Keyword Analysis & Research: catalyst pharmaceuticals
Keyword Research: People who searched catalyst pharmaceuticals also searched
Search Results related to catalyst pharmaceuticals on Search Engine
-
Catalyst: A Biopharmaceutical Company Focused on Rare Diseases
https://catalystpharma.com/
WEBThe innovation behind a breakthrough. Our company is committed to developing novel, safe, and efficacious therapies to improve the lives of people with rare diseases.
DA: 72 PA: 43 MOZ Rank: 91
-
Investors : Catalyst Pharmaceutical
https://ir.catalystpharma.com/
WEBMar 12, 2024 · Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases.
DA: 28 PA: 49 MOZ Rank: 10
-
Catalyst Pharmaceuticals, Inc. (CPRX) - Yahoo Finance
https://finance.yahoo.com/quote/CPRX
WEBCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and...
DA: 63 PA: 44 MOZ Rank: 55
-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial …
https://finance.yahoo.com/news/catalyst-pharmaceuticals-report-first-quarter-120000350.html
WEB2 days ago · The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or ...
DA: 93 PA: 92 MOZ Rank: 75
-
About Catalyst: Our Mission, Our Values, Our Work
https://catalystpharma.com/about-catalyst/
WEBCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. Our mission To improve the lives of patients with rare and ultra-rare diseases
DA: 84 PA: 16 MOZ Rank: 58
-
Research & Pipeline - catalystpharma.com
https://catalystpharma.com/research-pipeline/
WEBCatalyst is investing in the science of possibility—discovering, developing, and delivering innovative, life-changing medicines and solutions to transform patients’ lives and address their most important unmet medical needs.
DA: 47 PA: 62 MOZ Rank: 66
-
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full …
https://finance.yahoo.com/news/catalyst-pharmaceuticals-reports-strong-fourth-230300728.html
WEBFeb 28, 2024 · Catalyst Pharmaceuticals, Inc. Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022. Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million,...
DA: 2 PA: 99 MOZ Rank: 16
-
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® …
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fda-approval-agamreer
WEBCORAL GABLES, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals ("Santhera") has obtained U.S. Food and Drug Administration ("FDA") approval for AGAMREE ® (vamorolone) oral suspension 40 mg/mL for use in treating …
DA: 5 PA: 8 MOZ Rank: 94
-
Catalyst Pharmaceuticals - Wikipedia
https://en.wikipedia.org/wiki/Catalyst_Pharmaceuticals
WEBCatalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. The company is developing medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS).
DA: 2 PA: 68 MOZ Rank: 41
-
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year …
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fourth-quarter-and-full-year-0
WEBMar 15, 2023 · Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update. March 15, 2023 at 4:11 PM EDT. Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase. Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase.
DA: 57 PA: 48 MOZ Rank: 100
